These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22161846)

  • 1. From the observation DAC: romidepsin revisited.
    Knop S
    Blood; 2011 Dec; 118(24):6231-2. PubMed ID: 22161846
    [No Abstract]   [Full Text] [Related]  

  • 2. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
    Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
    Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.
    Fett NM; Toporcer MB; Dalmau J; Shinohara MM; Vogl DT
    Am J Hematol; 2011 Oct; 86(10):893-6. PubMed ID: 22026006
    [No Abstract]   [Full Text] [Related]  

  • 4. Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.
    Cavenagh JD
    Haematologica; 2006 Jul; 91(7):869B. PubMed ID: 16818270
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe intestinal vasculitis in a patient under treatment with bortezomib.
    Mangiacavalli S; Zappasodi P; Castagnola C; Astori C; Varettoni M; Lazzarino M; Corso A
    Ann Hematol; 2007 Dec; 86(12):923-4. PubMed ID: 17641890
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
    Ramadan KM; McKenna KE; Morris TC
    Lancet Oncol; 2006 Nov; 7(11):958-9. PubMed ID: 17081923
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib and lenalidomide effective in myeloma.
    Cancer Biol Ther; 2007 Jan; 6(1):5. PubMed ID: 17612004
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib plus doxorubicin combination slows progression of multiple myeloma.
    Cancer Biol Ther; 2007 Jan; 6(1):9-10. PubMed ID: 17612007
    [No Abstract]   [Full Text] [Related]  

  • 11. A third-generation IMiD for MM.
    Cavo M
    Blood; 2011 Sep; 118(11):2931-2. PubMed ID: 21921051
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
    Ito C; Aisa Y; Mihara A; Nakazato T
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):83-5. PubMed ID: 23103083
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.
    Decaux O; Clément M; Magrangeas F; Gouraud W; Charbonnel C; Campion L; Loiseau HA; Minvielle S
    Cancer Sci; 2010 Apr; 101(4):889-97. PubMed ID: 20100206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
    Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
    Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
    Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib in multiple myeloma.
    Vandenbroucke JP; Kroep JR
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
    [No Abstract]   [Full Text] [Related]  

  • 18. Life beyond bortezomib: increasing treatment options in refractory myeloma.
    Chakraborty R; Gertz MA
    Leuk Lymphoma; 2016; 57(6):1251-3. PubMed ID: 26926712
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem transplants in the treatment of multiple myeloma. Pro.
    Fassas AB; Tricot G
    Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.